Make sure you are at the forefront of the orphan drug industry. Regardless of whether your interest lies in research, clinical development, patient access, global pricing and reimbursement or just to engage with patient advocacy groups more intimately, we have content, networking and potential partners for you!
By bringing experts from patients and all stakeholders under one roof, you get to choose the sessions which are the most applicable to help your business plan for the future of orphan drug research, development and manufacture.
Take just three days out of the office to meet with 450+ potential customers who need to find solutions to challenges around the commercial, regulatory and scientific issues in orphan drugs.
Key speakers include:
Yann Le Cam, Chief Executive Officer, EURORDIS
Dr S茅gol猫ne Aym茅, Founder of Orphanet, Emeritus Research Director, INSERM
Dr Bruno Sepodes, Chair of the Committee of Orphan Medicinal Products, EMA
Sheela Upadhyaya, Associate Director Highly Specialised Technologies Centre for Health Technology Evaluation, National Institute for Health and Care Excellence
Dr Paul Strijbos, Global Head Rare Disease Clinical Development, Roche
Hugo Gomes da Silva, VP, Head of Global Medical affairs, Rare Diseases and Gene Therapy, GSK
Fl贸ra Raffai, Executive Director, Findacure
Peter Saltonstall, Chief Executive Officer, NORD
Nicole Boice, Founder & Chief Executive Officer, Global Genes
Aoife Brennan, VP Research and Development, Rare Diseases, Biogen
Scott Schliebner, Vice President, Scientific Affairs at PRA Health Sciences, PRA
Daniel Mazzolenis, Senior Medical Director, Global Oncology-Hematology, INC Research
Carlo Tomino, Head of Clinical Research, IRCCS San Raffaele
Dr Will Maier, Chief Scientific Officer, Mapi
Mauricio Berdugo, Associate Director, Health Science Executive, Ofev, Boehringer Ingelheim
By bringing experts from patients and all stakeholders under one roof, you get to choose the sessions which are the most applicable to help your business plan for the future of orphan drug research, development and manufacture.
Take just three days out of the office to meet with 450+ potential customers who need to find solutions to challenges around the commercial, regulatory and scientific issues in orphan drugs.
Key speakers include:
Yann Le Cam, Chief Executive Officer, EURORDIS
Dr S茅gol猫ne Aym茅, Founder of Orphanet, Emeritus Research Director, INSERM
Dr Bruno Sepodes, Chair of the Committee of Orphan Medicinal Products, EMA
Sheela Upadhyaya, Associate Director Highly Specialised Technologies Centre for Health Technology Evaluation, National Institute for Health and Care Excellence
Dr Paul Strijbos, Global Head Rare Disease Clinical Development, Roche
Hugo Gomes da Silva, VP, Head of Global Medical affairs, Rare Diseases and Gene Therapy, GSK
Fl贸ra Raffai, Executive Director, Findacure
Peter Saltonstall, Chief Executive Officer, NORD
Nicole Boice, Founder & Chief Executive Officer, Global Genes
Aoife Brennan, VP Research and Development, Rare Diseases, Biogen
Scott Schliebner, Vice President, Scientific Affairs at PRA Health Sciences, PRA
Daniel Mazzolenis, Senior Medical Director, Global Oncology-Hematology, INC Research
Carlo Tomino, Head of Clinical Research, IRCCS San Raffaele
Dr Will Maier, Chief Scientific Officer, Mapi
Mauricio Berdugo, Associate Director, Health Science Executive, Ofev, Boehringer Ingelheim
